|
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for …
PR Newswire (press release) In the filing, CTI proposed to the FDA that the randomized study will compare pixantrone plus rituximab against the current standard regimens used to treat … |
